- Calcify uremic arteriolopathy drug refers to pharmaceutical treatments designed to manage calciphylaxis, a rare and serious condition characterized by calcification and thrombosis of small blood vessels, leading to painful skin ulcers and high mortality, especially in patients with end-stage renal disease (ESRD)
- The surge in the prevalence of ESRD, increasing use of dialysis, and heightened awareness about rare vascular calcification disorders such as calciphylaxis are major factors accelerating the growth of the market
- The increase in clinical trials, development of novel therapies like SNF472 and sodium thiosulfate, and growing focus on orphan drug designation further influence market expansion
- North America is expected to dominate the sunburn treatment market with a share of 34 9%, driven by a strong over-the-counter product market, advanced dermatology infrastructure, and high public awareness of sun protection and treatment measures
- Asia-Pacific is expected to be the fastest growing region in the sunburn treatment market during the forecast period due to increasing urbanization, growing disposable income, rising incidence of sunburn cases, and expansion in retail pharmacy networks
- The chelating agents segment is expected to dominate the market with a market share of 30 7% due to its role in neutralizing free radicals and reducing oxidative stress in sun-damaged skin Although other drug classes like analgesics and antibiotics are also used, chelating agents are preferred for their skin repair properties and minimal side effects
